Biosensors’ Iconic Microcatheter Evaluated in BIOMICS Pivotal Trial in United Kingdom

April 5, 2022—Biosensors International Group, Ltd. announced the enrollment of the first patient in BIOMICS, a prospective, multicenter evaluation of the safety and effectiveness of the Biosensors microcatheter in patients undergoing percutaneous coronary intervention for the treatment of chronic total occlusions (CTOs).

Biosensors is conducting the BIOMICS study as part of their product development activities for the new Iconic coronary microcatheter.

The trial will include up to 10 sites in the United Kingdom and is being led by Margaret McEntegart, MD, and James Spratt, MD. Dr. McEntegart is from Golden Jubilee National Hospital in Glasgow, United Kingdom. Dr. Spratt is from St George’s Hospital in London, United Kingdom.

The first patients in the BIOMICS study were enrolled by Dr. McEntegart and Aadil Shaukat, MBBS, at the Golden Jubilee National Hospital.

In the company’s press release, Drs. McEntegart and Shaukat commented, “We are very excited to have performed the first-in-human cases with the new microcatheter from Biosensors as part of the BIOMICS study here at Golden Jubilee National Hospital. The new microcatheter was successful in crossing the CTO with no complications. We look forward to recruiting more patients in coming weeks.”